

Serena Di Cosimo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4629744/publications.pdf>

Version: 2024-02-01

211
papers

7,893
citations

76322

40
h-index

53222

85
g-index

220
all docs

220
docs citations

220
times ranked

12345
citing authors

#	ARTICLE	IF	CITATIONS
1	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012, 379, 633-640.	13.7	1,165
2	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 628-638.	6.3	769
3	NVP-BE2235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. <i>Cancer Research</i> , 2008, 68, 8022-8030.	0.9	726
4	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology, The</i> , 2014, 15, 1137-1146.	10.7	382
5	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	1.6	315
6	Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225). <i>Clinical Cancer Research</i> , 2004, 10, 6487-6501.	7.0	273
7	Management of breast cancer with targeted agents: importance of heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 139-147.	27.6	143
8	Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. <i>Drugs of Today</i> , 2003, 39, 157.	2.4	141
9	Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. <i>Annals of Oncology</i> , 2012, 23, 897-902.	1.2	135
10	¹⁸ F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1862-1868.	5.0	132
11	Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients. <i>Oncology</i> , 2005, 69, 35-43.	1.9	119
12	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	7.1	118
13	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	1.6	116
14	A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 6304-6312.	7.0	113
15	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	4.5	113
16	microRNAs in breast cancer development and treatment. <i>Cancer Treatment Reviews</i> , 2014, 40, 595-604.	7.7	111
17	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. <i>Annals of Oncology</i> , 2013, 24, 2715-2724.	1.2	106
18	Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. <i>Cancer</i> , 2004, 101, 133-138.	4.1	94

#	ARTICLE	IF	CITATIONS
19	Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005, 23, 6908-6918.	1.6	92
20	Targeted therapies in breast cancer: Where are we now?. <i>European Journal of Cancer</i> , 2008, 44, 2781-2790.	2.8	78
21	A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. <i>Annals of Oncology</i> , 2006, 17, 630-636.	1.2	73
22	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	7.0	73
23	Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2003, 21, 3462-3468.	1.6	72
24	Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2009, 15, 307-314.	7.0	65
25	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	2.1	61
26	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. <i>Annals of Oncology</i> , 2012, 23, 1130-1137.	1.2	60
27	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	1.6	60
28	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 858-871.	10.7	60
29	Abstract S3-3: First Results of the NeoALTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer. <i>Cancer Research</i> , 2010, 70, S3-3-S3-3.	0.9	58
30	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTO (BIG 1-06) and ALTO (BIG 1-06) trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 3008-3008.	1.6	58
31	Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. <i>Annals of Oncology</i> , 2004, 15, 1065-1071.	1.2	53
32	A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3008-3008.	1.6	53
33	Survival outcomes of the NeoALTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	2.8	51
34	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 49-59.	7.0	49
35	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	2.5	49
36	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. <i>Breast</i> , 2008, 17, 499-505.	2.2	47

#	ARTICLE	IF	CITATIONS
37	Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179.	4.4	47
38	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. <i>Seminars in Cancer Biology</i> , 2017, 44, 106-116.	9.6	47
39	Better Together: Targeted Combination Therapies in Breast Cancer. <i>Seminars in Oncology</i> , 2015, 42, 887-895.	2.2	45
40	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3887-3895.	7.0	42
41	Gemcitabine-induced atrial fibrillation: A hitherto unreported manifestation of drug toxicity. <i>Annals of Oncology</i> , 2000, 11, 479-481.	1.2	40
42	Heart to heart with trastuzumab: a review on cardiac toxicity. <i>Targeted Oncology</i> , 2011, 6, 189-195.	3.6	37
43	Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?. <i>Journal of Clinical Oncology</i> , 2006, 24, 3048-3055.	1.6	35
44	Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients. <i>Cancer Investigation</i> , 2007, 25, 102-105.	1.3	35
45	SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 351-357.	2.5	35
46	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma. <i>Cancer</i> , 2005, 104, 1335-1342.	4.1	34
47	Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. <i>British Journal of Cancer</i> , 2006, 94, 1789-1796.	6.4	34
48	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. <i>Oncotarget</i> , 2015, 6, 28173-28182.	1.8	34
49	Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. <i>Cancer</i> , 2005, 104, 1237-1245.	4.1	33
50	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	2.2	33
51	Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. <i>British Journal of Cancer</i> , 2018, 119, 1487-1494.	6.4	33
52	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	4.1	33
53	Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. <i>Annals of Oncology</i> , 2013, 24, 1980-1985.	1.2	32
54	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020, 135, 62-65.	2.8	32

#	ARTICLE	IF	CITATIONS
55	Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3112-3112.	1.6	32
56	Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. <i>Breast</i> , 2016, 29, 90-95.	2.2	31
57	Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2021, 6, 100086.	4.5	31
58	NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 133.	5.0	30
59	Phosphoinositide 3-Kinase Mutations in Breast Cancer: A "Good" Activating Mutation?. <i>Clinical Cancer Research</i> , 2009, 15, 5017-5019.	7.0	29
60	Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. <i>Breast</i> , 2013, 22, 19-23.	2.2	27
61	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 429-433.	1.8	26
62	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020, 60, 344-350.	9.6	26
63	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	3.7	26
64	Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. <i>Acta Oncologica</i> , 2003, 42, 693-700.	1.8	22
65	Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 425-437.	2.5	22
66	Advancing immunotherapy for early-stage triple-negative breast cancer. <i>Lancet</i> , The, 2020, 396, 1046-1048.	13.7	20
67	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 462-470.	6.3	20
68	The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3511-3511.	1.6	20
69	Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. <i>Annals of Oncology</i> , 2003, 14, 803-804.	1.2	18
70	Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. <i>Supportive Care in Cancer</i> , 2005, 13, 375-380.	2.2	18
71	Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. <i>Tumori</i> , 2016, 102, e11-e14.	1.1	18
72	Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin. <i>Annals of Oncology</i> , 2003, 14, 1689-1690.	1.2	16

#	ARTICLE	IF	CITATIONS
73	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	3.7	16
74	Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. <i>Breast Cancer Research</i> , 2020, 22, 115.	5.0	16
75	Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?. <i>Clinical Breast Cancer</i> , 2018, 18, e363-e371.	2.4	14
76	Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies. <i>Clinical Breast Cancer</i> , 2016, 16, 327-334.	2.4	13
77	The use of breast imaging for predicting response to Neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. <i>European Journal of Cancer</i> , 2018, 89, 42-48.	2.8	13
78	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	7.1	13
79	Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 181-189.	4.9	13
80	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 467-470.	6.3	13
81	Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06). , 2013, , .		13
82	Role of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study. <i>SpringerPlus</i> , 2016, 5, 114.	1.2	12
83	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6156-6163.	7.0	12
84	Is there a benefit by the sequence anastrozole+formestane for postmenopausal metastatic breast cancer women?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 86, 107-109.	2.5	11
85	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	2.8	11
86	Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer. <i>Medical Oncology</i> , 2019, 36, 4.	2.5	11
87	CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer. <i>Breast</i> , 2021, 55, 75-78.	2.2	11
88	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 1.	0.7	10
89	HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature. <i>Breast Care</i> , 2016, 11, 424-426.	1.4	10
90	Trastuzumab Cardiac Toxicity: A Problem we Put our Heart Into. <i>Tumori</i> , 2016, 102, 1-5.	1.1	10

#	ARTICLE	IF	CITATIONS
91	Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 1470.	3.3	10
92	Management of the axilla in early breast cancer patients in the genomic era. <i>Annals of Oncology</i> , 2013, 24, 1163-1170.	1.2	9
93	Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. <i>Breast Care</i> , 2017, 12, 391-394.	1.4	9
94	Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients: Clinical Evaluation of an Italian Experience. <i>Clinical Breast Cancer</i> , 2018, 18, e1059-e1066.	2.4	9
95	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	5.2	9
96	Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer – Moving beyond pathological complete response. <i>Breast</i> , 2014, 23, 188-192.	2.2	8
97	Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. <i>Medical Oncology</i> , 2018, 35, 107.	2.5	8
98	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021, 13, 1324.	3.7	8
99	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	7.0	8
100	Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 512-512.	1.6	8
101	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2019, 37, 574-574.	1.6	8
102	Catheter-Related Bloodstream Infections, Part I: Pathogenesis, Diagnosis, and Management. <i>Cancer Control</i> , 2002, 9, 513-523.	1.8	7
103	Axillary Coverage by Whole Breast Irradiation in 1 to 2 Positive Sentinel Lymph Nodes in Breast Cancer Patients. <i>Tumori</i> , 2016, 102, 409-413.	1.1	7
104	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020, 12, 3509.	3.7	7
105	Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). <i>Journal of Clinical Oncology</i> , 2004, 22, 3074-3074.	1.6	7
106	Subacute motor weakness and left renal mass. <i>American Journal of Medicine</i> , 2003, 114, 706-708.	1.5	6
107	Lack of Response to Imatinib Mesylate as Second-Line Therapy in a Patient with C-Kit Positive Metastatic Soft Tissue Leiomyosarcoma. <i>Tumori</i> , 2005, 91, 103-103.	1.1	6
108	Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?. <i>Annals of Oncology</i> , 2005, 16, 1209-1210.	1.2	6

#	ARTICLE	IF	CITATIONS
109	P124 neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 1-06/SOLTI/EGF106903]: a phase III translational study for Her2-overexpressing early breast cancer (BC). <i>Breast</i> , 2007, 16, S48.	2.2	6
110	Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. <i>Breast</i> , 2014, 23, 690-691.	2.2	6
111	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. <i>PLoS ONE</i> , 2019, 14, e0220644.	2.5	6
112	Interobserver variability (between radiation oncologist and radiation therapist) in tumor bed contouring after breast-conserving surgery. <i>Tumori</i> , 2019, 105, 210-215.	1.1	6
113	Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). <i>Journal of Clinical Oncology</i> , 2004, 22, 3074-3074.	1.6	6
114	What if the future of HER2 ⁺ positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. <i>Cancer Medicine</i> , 2022, 11, 332-339.	2.8	6
115	Gastric Stump Lymphoma Five Years After Distal Gastrectomy. <i>Leukemia and Lymphoma</i> , 2003, 44, 365-367.	1.3	5
116	HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear?. <i>Journal of Clinical Oncology</i> , 2004, 22, 568-569.	1.6	5
117	Effect of Filgrastim on Serum Lactate Dehydrogenase and Alkaline Phosphatase Values in Early Breast Cancer Patients. <i>Cancer Investigation</i> , 2004, 22, 650-653.	1.3	5
118	Pharmacodynamic endpoints in primary breast cancer. <i>Annals of Oncology</i> , 2007, 18, ix21-ix23.	1.2	5
119	Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy. <i>Breast Cancer Research</i> , 2009, 11, S25.	5.0	5
120	Complete remission in metastatic breast cancer: expecting the unexpected results of a cross-sectional study. <i>Breast Cancer</i> , 2017, 24, 635-641.	2.9	5
121	Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. <i>Breast</i> , 2017, 35, 63-68.	2.2	5
122	Older age and comorbidity in breast cancer: is RT alone the new therapeutic frontier?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1791-1800.	2.5	5
123	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5607-5618.	7.0	5
124	SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1011-1011.	1.6	5
125	Covid-19 outbreak in Lombardy: impact on reducing solid cancer diagnoses in 2020. <i>International Journal of Cancer</i> , 0, , .	5.1	5
126	Breast Cancer Metastatic to the Choroid in a Male Patient Case Report. <i>Tumori</i> , 2003, 89, 333-335.	1.1	4

#	ARTICLE	IF	CITATIONS
127	Exploratory phase II study of celecoxib and infusional fluorouracil as second-line treatment for advanced pancreatic (PDAC) and biliary tree cancer (BTC). <i>Journal of Clinical Oncology</i> , 2004, 22, 4183-4183.	1.6	4
128	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. <i>Oncotarget</i> , 2016, 7, 67956-67965.	1.8	4
129	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	4
130	Catheter-Related Bloodstream Infections, Part II: Specific Pathogens and Prevention. <i>Cancer Control</i> , 2003, 10, 79-91.	1.8	3
131	5013 ORAL FDG-PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-positive Breast Cancer Patients: the Neo-ALTTO Study Results. <i>European Journal of Cancer</i> , 2011, 47, S333-S334.	2.8	3
132	Prognosis of women with early breast cancer and PIK3CA mutations. <i>Breast</i> , 2015, 24, 283-284.	2.2	3
133	Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patients. <i>Breast</i> , 2018, 40, 131-135.	2.2	3
134	Circulating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial. <i>Annals of Oncology</i> , 2019, 30, iii28-iii29.	1.2	3
135	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989160.	3.2	3
136	Hypofractionated irradiation in 794 elderly breast cancer patients: An observational study. <i>Breast Journal</i> , 2020, 26, 188-196.	1.0	3
137	VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30Â°Cy in five daily fractions. <i>Clinical and Translational Oncology</i> , 2020, 22, 1802-1808.	2.4	3
138	Automated breast ultrasound compared to hand-held ultrasound in surveillance after breast-conserving surgery. <i>Tumori</i> , 2021, 107, 132-138.	1.1	3
139	Abstract P1-09-09: Efficacy and gene expression results from SOLT11007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. , 2017, , .		3
140	Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2007, 25, 1066-1066.	1.6	3
141	Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2010, 28, 628-628.	1.6	3
142	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2â€positive and ERâ€positive breast cancer patients: an explorative analysis from the NeoSphere trial. <i>Molecular Oncology</i> , 2022, 16, 2355-2366.	4.6	3
143	Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. , 2022, 10, e004820.		3
144	Can Colorectal Cancer Patients With Thymidylate Synthaseâ€Overexpressing Liver Metastases Have an Overall Survival Advantage With Hepatic Arterial Infusion Alone?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3543-3544.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. <i>Breast</i> , 2006, 15, 269-272.	2.2	2
146	Clinical Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab: The Potential of the Time to Relapse. <i>Clinical Oncology</i> , 2014, 26, 174.	1.4	2
147	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. <i>Clinical and Translational Oncology</i> , 2015, 17, 530-538.	2.4	2
148	Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. <i>European Journal of Cancer</i> , 2020, 138, S15-S16.	2.8	2
149	Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. <i>Frontiers in Oncology</i> , 2020, 10, 1223.	2.8	2
150	Hypofractionated whole-breast radiotherapy in large breast size patients: is it really a resolved issue?. <i>Medical Oncology</i> , 2021, 38, 107.	2.5	2
151	Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer â€œ NeoPHOEBE. <i>Cancer Research</i> , 2013, 73, OT2-6-08-OT2-6-08.	0.9	2
152	Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 10067-10067.	1.6	2
153	Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1543-1550.	2.5	2
154	Suspected Pharmacological Interactions in a Cancer Patient During Methadone Maintenance. <i>Addictive Disorders and Their Treatment</i> , 2004, 3, 87-92.	0.5	1
155	Correlation Between Circulating Tumor Cells (CTCS), PET/CT Response And Pathological Complete Response (PCR) in Primary HER2-Positive (HER2+) Breast Cancer Patients: A Sub-Study From the Neoalto Trial. <i>Annals of Oncology</i> , 2012, 23, ix98.	1.2	1
156	The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoalto Trial (BIG 1-06). <i>Annals of Oncology</i> , 2012, 23, ix4.	1.2	1
157	Re: Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1912-1912.	6.3	1
158	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. <i>Breast</i> , 2016, 27, 187-188.	2.2	1
159	Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice. <i>Annals of Oncology</i> , 2019, 30, v718.	1.2	1
160	Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 786-792.	2.4	1
161	59P Primary tumour and circulating tumour cell (CTC) copy number alterations (CNAs) in triple negative breast cancer (TNBC) patients (pts) treated with neoadjuvant chemotherapy (NAC). <i>Annals of Oncology</i> , 2020, 31, S35-S36.	1.2	1
162	Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2020, 31, 435-437.	1.2	1

#	ARTICLE	IF	CITATIONS
163	P5-13-01: Survival Outcome with Bevacizumab: Activation of the Phosphatidylinositol-3 Kinase (PI3K) Pathway Due to PIK3CA Mutations or PTEN Loss Makes a Difference.. , 2011, , .		1
164	Abstract P3-07-66: Efficacy and gene expression results from eribulin SOLT11007 neoadjuvant study. , 2016, , .		1
165	A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, TPS625-TPS625.	1.6	1
166	Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m ² of doxorubicin (D).. Journal of Clinical Oncology, 2010, 28, 1112-1112.	1.6	1
167	Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.. Journal of Clinical Oncology, 2018, 36, 577-577.	1.6	1
168	Long-Term Follow-Up in Breast Cancer Survivors: A Single Institution Survey. Journal of Women's Health, 2003, 12, 599-600.	3.3	0
169	Fatal Thrombocytopenia and Thrombocytopathia: An Unusual Onset of Non-Small Cell Lung Cancer. Oncology Research and Treatment, 2003, 26, 272-274.	1.2	0
170	Correction: Article on TLC-D99, Paclitaxel, Trastuzumab in HER-2 Breast Cancer. Clinical Cancer Research, 2009, 15, 1843-1843.	7.0	0
171	5064 POSTER Breast Cancer Subtype and Survival in Metastatic Patients Treated With Bevacizumab. European Journal of Cancer, 2011, 47, S349.	2.8	0
172	1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. European Journal of Cancer, 2015, 51, S269.	2.8	0
173	It's not the quality but the quantity: tumor mutation spectrum and response to neoadjuvant therapy in triple negative breast cancer. Annals of Oncology, 2016, 27, iv70.	1.2	0
174	Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): Analysis from NeoALLTO trial. Annals of Oncology, 2016, 27, vi57.	1.2	0
175	Breast cancer Ki67, tumor size and axillary nodes relationship: it's complicated. Annals of Oncology, 2016, 27, vi49.	1.2	0
176	Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history. Breast Cancer, 2017, 24, 491-492.	2.9	0
177	PO-0662: Target therapy and hypofractionated whole breast radiotherapy: an unexpected protective factor. Radiotherapy and Oncology, 2017, 123, S345-S346.	0.6	0
178	Time to surgery after neoadjuvant chemotherapy for early breast cancer. Annals of Oncology, 2017, 28, vi29.	1.2	0
179	Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial. Annals of Oncology, 2017, 28, v50.	1.2	0
180	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoSphere study. European Journal of Cancer, 2018, 92, S8.	2.8	0

#	ARTICLE	IF	CITATIONS
181	Multicenter phase I trial of trastuzumab emtansine (T-DM1) in combination with non-pegylated liposomal doxorubicin (NPLD) in HER2[+] metastatic breast cancer (MBC). THELMA study. <i>Annals of Oncology</i> , 2019, 30, v124-v125.	1.2	0
182	EP-1284 Older age and comorbidity in breast cancer: is radiotherapy alone the new therapeutic frontier?. <i>Radiotherapy and Oncology</i> , 2019, 133, S703-S704.	0.6	0
183	EP-1285 Hypofractionated irradiation in elderly breast cancer patients: an observational study. <i>Radiotherapy and Oncology</i> , 2019, 133, S704.	0.6	0
184	RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1232-1233.	6.3	0
185	Gene Profiles in Breast Cancer. , 2019, , 351-361.		0
186	High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer. <i>Tumori</i> , 2020, 106, 64-69.	1.1	0
187	Anticancer innovative therapy: Highlights from the ninth annual meeting. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 1-9.	7.2	0
188	153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials. <i>Annals of Oncology</i> , 2020, 31, S71.	1.2	0
189	Nobody dares stopping clinical research, not even COVID-19. <i>Npj Breast Cancer</i> , 2021, 7, 39.	5.2	0
190	Timing of adjuvant chemotherapy by menstrual cycle phase and risk of secondary amenorrhea in women with early breast cancer: Preliminary results. <i>Journal of Clinical Oncology</i> , 2004, 22, 780-780.	1.6	0
191	Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matters?. <i>Journal of Clinical Oncology</i> , 2009, 27, e20527-e20527.	1.6	0
192	Timing of re-excision surgery (S2) for positive margins (PM) and initiation of adjuvant systemic treatment (aRx) in early breast cancer patients (BC pts).. <i>Journal of Clinical Oncology</i> , 2010, 28, e11065-e11065.	1.6	0
193	Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).. <i>Journal of Clinical Oncology</i> , 2010, 28, 1113-1113.	1.6	0
194	Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 1081-1081.	1.6	0
195	Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A).. <i>Journal of Clinical Oncology</i> , 2011, 29, 1074-1074.	1.6	0
196	P5-11-12: Correlation of Ki67 Expression between Initial Biopsy and Surgical Specimen in Untreated Breast Cancer Patients. Does Menstrual Cycle Matter?. , 2011, , .		0
197	P3-07-21: Sentinel Lymph Node Metastasis Are More Likely To Develop in Triple Positive Breast Cancer Patients without Compromising Disease Free Survival.. , 2011, , .		0
198	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , 2012, 30, 619-619.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Abstract OT3-3-06: NeoEribulin: A Phase II, non-randomized, open-label, single-arm, multicenter, exploratory pharmacogenomic study of single agent eribulin as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer.. , 2012, , .		0
200	Abstract P4-12-22: Time to relapse (TTR) is a potential discriminator of clinical outcome in HER2-positive breast cancer (BC) patients (pts) progressing on adjuvant trastuzumab (AdjT). , 2013, , .		0
201	HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression.. Journal of Clinical Oncology, 2014, 32, e11591-e11591.	1.6	0
202	The natural history of HER2-overexpressing (HER2+) metastatic breast cancer (MBC) treated with trastuzumab (T): Practical points to consider in developing treatment strategies.. Journal of Clinical Oncology, 2014, 32, e11565-e11565.	1.6	0
203	Abstract P1-14-22: Neo-adjuvant chemotherapy for the treatment of breast cancer exerts a selection pressure toward luminal phenotype. , 2016, , .		0
204	Abstract P2-06-07: Risk of metastases after ipsilateral breast tumour recurrence changes overtime according to patient and tumour characteristics: Implications for treatment. , 2017, , .		0
205	Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO. , 2017, , .		0
206	Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG) Tj ETQq0.0 0 rgBT0Overlock		0
207	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570.	1.6	0
208	Effect of gender on the outcome of patients receiving nivolumab for metastatic renal cancer: Results from a large study population.. Journal of Clinical Oncology, 2019, 37, e16087-e16087.	1.6	0
209	Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial. , 2019, , .		0
210	Fixed dose-rate gemcitabine (GEM) infusion in advanced pancreatic (PDAC) and biliary tree (BTC) carcinoma: A phase II study. Journal of Clinical Oncology, 2004, 22, 4182-4182.	1.6	0
211	Brain metastases in HER2-positive breast cancer: challenges and opportunities. Annals of Palliative Medicine, 2012, 1, 195-7.	1.2	0